Phoenix Biotech

Precigen $pgen overreaction to the $ino news. Their drug was not approved like Precigen’s is. Inovio still has work to do 👇 “The agency based this accelerated approval on clinical trial data showing Voceryq helps reduce the frequency of surgical procedures required to remove growths in adult patients with RRP — an intermediate clinical endpoint reasonably likely to predict clinical benefit. The accelerated approval pathway allows the FDA to approve drugs or biologics for serious or life-threatening conditions based on an effect on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit. The manufacturer must conduct post-approval clinical trials to verify and describe Voceryq’s clinical benefit.”